第30åæ¡æ©WEBãã³ãºãªã³ã»ãããŒ
å®æœæ¥ã2020幎11 æ14æ¥ãå ŽæãããªãŒãŒãã©ã¶8éïŒã¹ã¿ãžãªé ä¿¡ïŒã
ã530-0001 倧éªåžååºæ¢ ç°2-4-9 ããªãŒãŒã¿ã¯ãŒ8é ãïŒèšç»æ¿èª:èªå®æ¿èªæžïŒ
æ¬å¹ŽæåŸã®WEBãã³ãºãªã³ã»ãããŒãéå¬ããããŸãããïŒæè²å§å¡äŒèªå®2020/10/13ïŒ
ç¹å¥è¬æŒã¯ãæ°æœå€§åŠå»æ¯åŠç·åç é¢ æŸå°ç·éš ç é¢ææ åæ 宣圊 å çã«ãç»å£ããã ããŸããã
ãå¿è CT ã§ééããéå åèçŸæ£ãã®ãè¬æŒãããã ããæ¥åžžèšåºã§ééããéå åèçŸæ£ãèŠèŽè ã®ã¿ãªããã«ããããããããäžå¯§ã«æããŠé ããŸãããææ¥ããèšåºã«åœ¹ç«ã€å 容ã§ãåå ã®çããã倧å€æºè¶³ãããŠãããŸããã
ãç¹å¥è¬æŒã«åŒãç¶ããã¯ãŒã¯ã¹ããŒã·ã§ã³ã«ããç»å解æãè¡ããŸããã
Case1ã§ã¯ãPROMISE trial ãWestern Denmark Heart RegistryãThe CONFIRM long-term registryã®å€§èŠæš¡ç 究ã®çµæãèžãŸãNon-obstractive stenosisçäŸã®Plaque managementæ¹æ³ãšPlaque regression解æãICONIC Studyã®çµæãèžãŸããå æ¬çãªãã©ãŒã¯è§£æã§è¡ããŸããã
ãå šãŠã®Case1ïœ3ã§ãthe CRISP CT studyã®Residual cardiovascular risk ãççã€ã¡ãŒãžã³ã°ã§ããPerivascular fat attenuation index (FAI)ã®èšæž¬ãèè¡èšºæã®FFR-CTããèè¡ãšççã®é¢é£ãå«ãäœéšããŠããããŸããã
ããŸããæšå¹Žã®ISCHEMIA StudyãèžãŸãããã€ãªã¹ã¯èè¡çäŸãšããŠã®Case2ã§ACSçŽåã®é«åºŠççªçäŸãšCase3ã§æ ¢æ§ã®é«åºŠççªã§ããCTOçäŸã®ç å€éšããããã®ç å€ã®ç»åäžã®ç¹åŸŽã®éãã解æããæ²»çã«ã€ããŠãæ€èšãå ããŸãããç¹ã«Case3ã¯ãæ²»çã€ã¡ãŒãžã³ã°ãšããŠè¡ç®¡ãççž®ããããšãªãå転ãããAngiographyã®AngleãCTããæ±ããå®éã®æ€èšãè¡ããŸããã
ãäºåæºåãæ©æã»ããã£ã³ã°ãé ä¿¡ãªã©ã¹ã¿ããã®æè¡ãååããåäžãWEBé ä¿¡ãäžéããŠããŸããããŸããä»åã¯ãïŒGãå©çšããé ä¿¡ãè¡ããŸããã以äžåçãæ·»ä»ããããŸãã
ã
13:30-14:15 ç¹å¥è¬æŒ ãå¿è CT ã§ééããéå åèçŸæ£ã
æ°æœå€§åŠå»æ¯åŠç·åç é¢ æŸå°ç·éš ç é¢ææ åæ 宣圊 å ç
14:20-17:30 ã¯ãŒã¯ã¹ããŒã·ã§ã³ã«ããç»å解æïŒïŒçäŸïŒ
奥ã«ç»åé ä¿¡ããŒã¹ãå³å¥¥ã«ã¯ãŒã¯ã¹ããŒã·ã§ã³ãµããŒãã¹ã¿ãããäžå€®é ä¿¡ãšãªã¢ïŒåºãéšå±ã§å¯ã«ãªããªãããã«é 眮ããææ°è£ 眮ãå©çšããŸããïŒãŸããã¯ãŒã¯ã¹ããŒã·ã§ã³åŸæ¹ã«ã¢ãã¿ãŒçšã®ãããžã§ã¯ã·ã§ã³ãè¡ããŸããããŸãããã€ãã®çäŸååãä»åãã埩掻ããåå è ã®çæ§ã®ãæå ã«ãå±ãã§ããŸããã
Camera1ãšCameraïŒã®çºèšè éã¯ææäºé²å¯Ÿçã®ããã¢ã¯ãªã«æ¿ã§ä»åããèšããŸããã
ä»åã¯ïŒGã§ã®é ä¿¡ãè¡ããŸããã
åååæ§ã«ã¯ãŒã¯ã¹ããŒã·ã§ã³ã¯çŽ°éšãŸã§ããèŠãåå解æã§ããŸããã
åååæ§ã«FAIã綺éºã«çºè²ããŠããèŠããŸããïŒæè²çšããã°ã©ã ïŒã
ææäºé²å¯Ÿçã®ããã¢ã¯ãªã«æ¿è¶ãã«ãã£ã¹ã«ãã·ã§ã³ãè¡ããŸããïŒCase2ïŒããŸããåå è ã®ã¯ãŒã¯ã¹ããŒã·ã§ã³ã«å ¥ãæè²çšè³æã䜿ããªãã説æããŸããïŒCase3ïŒã
ãšã³ãã£ã³ã°é¢šæ¯ïŒåå è ã®çæ§ããããšãããããŸããããŸããã¹ã¿ããã®çæ§ãç²ãæ§ã§ãããïŒ
å°ãæéã¯æŒããŸããããç¡äºã«çµããããšãã§ããŸããã
æåŸã«ãä»åã¯ååããå°ãé²æ©ããŸããã
ãCOVID19ã«ãããå€ãã®ã€ãã³ããèªç²ãäœåãªããããäžãæ¡æ©ãã³ãºãªã³ã»ãããŒãæ°ãã察çãèããããšã倧åãšæããæ¡æ©ãã³ãºãªã³ã»ãããŒã®ã¹ã¿ããéãšãç¥æµãçµã£ãŠã¯ãŒã¯ã¹ããŒã·ã§ã³ã䜿ããªããZoomã䜵çšããåŸæ¥éãã®åæ¹åã«ãã ãããé ä¿¡ã¯ãã¹ãŠã¹ã¿ããã§è¡ãããšã§è²»çšããããã ã«ãé ä¿¡ãè¡ããŸããã
ãä»åã¯ãæäŸã®èªå·±çŽ¹ä»ã®æéã埩掻ãåå è ãšã®äº€æµãã§ããããã«ãªã£ãŠããŸãããåå è ã®çæ§ã®ãããããå±ãŸããšãååãããã«ã¹ã¿ããã®å°œåã«æè¬ããããŸãã
ããŸããä»åãããïŒGåç·ã䜿ãããšã«ãªãããã®æè¡ãä»åŸã©ã®ããã«ãã³ãºãªã³ã»ãããŒã§æŽ»çšããŠããããšãã宿é¡ãããã ããŸããããããããããã«åæ¹åã«ãã ãããåå è ã®çæ§ãšãšãã«çºå±ããè¯ãç°å¢ãæäŸã§ããŸããã粟é²ããŠåããŸãããã®æ°ãããã³ãºãªã³ã»ãããŒã®éå¬ã«ãæ¿èªããã ããŸãããæè²å§å¡äŒã®å çæ¹ã«æ·±è¬ããããŸããæåŸã«ãªããŸãããããããŸã§å€å€§ãªãå°œåãšãååããã ããŸããå ±å¬äŒæ¥ã®çæ§ãããããšãããããŸããã
æ¡æ©æž¡èŸºç é¢
å°å±±éå²ãæ
å ±å¬
æ ªåŒäŒç€Ÿãã£ãªããã¹ãžã£ãã³
ãã€ãšã«è¬åæ ªåŒäŒç€Ÿ
åå ç¹å®å»çæ³äºº 枡蟺å»åŠäŒ æ¡æ©æž¡èŸºç é¢